From risk stratification to precision analgesia — What the POPIT trials teach us - 18/11/25
Doi : 10.1016/j.jclinane.2025.112069
Timur Yurttas a, Colin Royse b, c, d, Markus M. Luedi, MD, MBA a, e, ⁎ 
a Department of Anaesthesiology Rescue- and Pain Medicine, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
b Department of Surgery, the University of Melbourne, Carlton, Victoria, Australia
c Department of Anaesthesia and Pain Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia
d Outcomes Research, University of Texas Medical Center, Houston, Texas, USA
e Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
⁎Corresponding author at: Department of Anaesthesiology Rescue- and Pain Medicine, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.Department of Anaesthesiology Rescue- and Pain MedicineHOCH Health OstschweizCantonal Hospital St. GallenSt. GallenSwitzerland
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Tuesday 18 November 2025
Abstract |
N/A (editorial)
Le texte complet de cet article est disponible en PDF.Highlights |
• | The POPIT trials operationalize venous cannulation pain (VCP) as a rapid, preoperative marker of pain vulnerability. |
• | Low VCP identifies patients in whom opioid-free anesthesia (OFA) is safe, effective, and non-inferior to standard care. |
• | High VCP patients gain no measurable benefit from adding NMDA- or α₂-agonists to multimodal opioid regimens. |
• | Together, these findings reframe risk stratification as guidance for de-escalation rather than escalation of therapy. |
• | Precision analgesia thus means confidently giving less—when supported by objective data. |
Plan
© 2025
Elsevier Inc. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?